We are looking forward to attending this year’s Alzheimer’s Association International Conference (AAIC) in San Diego from 31st July to 4th August and learning about the latest developments in dementia research.
Cambridge Cognition Holdings is pleased to announce that it will be joining the University of California, San Francisco (UCSF) Brain Health Registry as a cognitive assessment partner. The Brain Health Registry is an online platform designed to speed up the discovery of treatments for Alzheimer's disease, Parkinson's disease, depression, post-traumatic stress disorder, and other brain disorders.
At the virtual ADPD 2021 event, Emily Thorp discussed engagement and adherence to remote testing in middle-aged adults at risk of dementia.
We caught up with researchers from the Division of Neuroscience and Experimental Psychology, University of Manchester to discuss the role that CANTAB plays in their cutting-edge neuroimaging study.
With more than two million participants, Dementias Platform UK is a national effort to make real strides in tackling dementia. Leona Wolters from the initiative shared with us the vital role that CANTAB plays in this large-scale cohort study.
At AD/PD 2019 we showed that automated, electronic cognitive testing is acceptable and feasible for patients presenting to clinic with Parkinson’s disease.
PhD researcher, Rosalyn Hithersay, spoke to us about her recent publication on which cognitive tests are most sensitive to the early stages of dementia in Down syndrome.
How can you tell if a decision was impulsive or risky? Using the Cambridge Gambling Task to unpick how different brain regions, different drugs and different dopamine levels impact on decision-making.
Cambridge Cognition is attending the Alzheimer's Association International Conference in London.